<DOC>
	<DOCNO>NCT02826031</DOCNO>
	<brief_summary>This multi-center , randomize , open-label , parallel-arm phase IV clinical study , total 300 patient mild moderate knee osteoarthritis enrol . In first 4 week ( run-in period ) , subject receive on-demand treatment Diclofenac Sodium Sustained Release Tablets ( DICL-SR ) 75mg , quaque die（QD） . After run-in period , subject , knee pain worsen level require surgical treatment , randomize two group 1:1 ratio : one group receive Artz® via intra-articular injection ( weekly , 5 consecutive week ) combination DICL-SR 75mg , quaque die（QD） , 12 consecutive week demand . The group receive DICL-SR 75mg alone , quaque die（QD） , 12 consecutive week demand . DICL-SR 75mg quaque die（QD） may administer subject group demand long knee pain . If knee pain disappear , drug may withdraw . However , pain occur require treatment , oral administration DICL-SR may resume . A subject allow withdraw study prematurely unable tolerate adverse effect . A total 8 visit schedule study , include Visit 1/screening period ( Week -4 ) , Visit 2/baseline ( Week 0 ) , Visit 3 ( Week 1 ) , Visit 4 ( Week 2 ) , Visit 5 ( Week 3 ) , Visit 6 ( Week 4 ) , Visit 7 ( Week 8 ) Visit 8 ( Week 12 ) . A total 300 subject participate study 6 8 center China , patient enrollment expect take 12 month .</brief_summary>
	<brief_title>Clinical Study Artz Treatment Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>1 . Adult Chinese subject , age≥18 , either gender , diagnose osteoarthritis target knee KellgrenLawrence ( KL ) classification Grade 1~3 , evidence Xray examination last 3 month ( mild moderate narrow joint space / mark osteophyte tibiofemoral joint space ) 2 . Persist pain target knee exercise , weight loss physical therapy ; 3 . A baseline WOMAC A1 score target knee rat 4090mm ( moderate severe walkassociated pain ) 100mm Visual analogue scale ( VAS ) ; Able understand sign Informed Consent Form ( ICF ) already approve Independent Ethics Committee ( IEC ) Note : informed consent may also give duly authorized representative subject . 1 . A diagnosis bilateral knee osteoarthritis ; 2 . Clinically significant ( require surgery ) valgus varus deformity knee joint , ligamentous laxity unstable meniscus ; 3 . Complicated inflammation disease /condition ( e.g. , rheumatic arthritis , metabolic bone disease , psoriasis , gout , pseudogout , chondrocalcinosis , etc . ) may affect knee joint ; 4 . A history septicemia , clinically consider subacute infection target knee joint ; 5 . A history surgery target knee ( last 6 month ) ; 6 . A history asthma , urticaria allergy use aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) ; 7 . Severe hepatic renal disease hepatic /renal failure ; 8 . Any unscheduled surgery lower limb ; 9 . Clinically significant low venous lymphatic obstruction ; 10 . Clinically significant obvious exudation inflammation target knee ; 11 . Skin disorder infection injection site ; 12 . Pregnant lactating woman ; 13 . Known allergy guanylin / active ingredient excipient hyaluronic acidbased injection / diclofenac sodium ; 14 . Treatment hyaluronic acid ( HA ) derivatives target knee within six month trial ; 15 . Intraarticular ( IA ) injection steroid target knee within 3 month trial ; 16 . Presence contraindication IA injection , e.g. , patient receive anticoagulation therapy clinically potential coagulation disorder ( e.g. , hepatic disease ) ; 17 . Presence clinically significant disease ( e.g. , significant mental nervous disorder , alcohol/drug abuse ) , unstable/poorly control disease , factor , may affect evaluation participation study investigator 's judgment 18 . Perioperative pain associate coronary artery bypass surgery ( CABG ) ; 19 . A history gastrointestinal bleeding perforation follow use NSAIDs ; 20 . Presence active gastrointestinal ulcer /bleeding , past history recurrent ulcer/bleeding ; Chief complaint complicate pain beyond target knee ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sodium Hyaluronate</keyword>
	<keyword>mild moderate knee osteoarthritis</keyword>
</DOC>